ArticleAdvances in therapy2023
Botulinum Toxin Utilization, Treatment Patterns, and Healthcare Costs Among Patients with Spasticity or Cervical Dystonia in the US.
Article in Advances in therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 6 citations in OpenAlex.
- Phenol Neurolysis for Refractory Non-Cancer Chronic Pain: Re-Evaluating an Established Technique in Modern Pain Practice.Current pain and headache reports · 2026Review
- Real-World Treatment Switch Rates, and Healthcare Costs of Botulinum Toxin Type A Among Patients with Cervical Dystonia in the USA: A Retrospective Claims Analysis.Neurology and therapy · 2026Article
- Non-Invasive Assessment of Hypertonic Muscle Properties After Botulinum Toxin Neuromodulation in Post-Stroke Patients: A Systematic Literature Review of Recent Evidence (2023-2025) on Mobility and Balance.Life (Basel, Switzerland) · 2026Review
- Article
- Real-World Switch Rates, Treatment Patterns, and Healthcare Costs Among Patients With Spasticity Treated With Botulinum Toxins.Advances in therapy · 2026Article
- Real-world use of botulinum toxin-A for post-stroke spasticity in the Netherlands: a retrospective claims study.Journal of rehabilitation medicine · 2026Observational
- Trends and off-label use of botulinum toxin type A in Chinese neurological practice from 2016 to 2023: a real-world study.Frontiers in pharmacology · 2026Article
- Nationwide Trends in Healthcare Utilization and Expenditures Among Patients with Cervical Dystonia in Korea: A 7-Year Analysis Using Health Insurance Data.Healthcare (Basel, Switzerland) · 2025Article
- Article
- Cryoneurolysis for Managing Spasticity in Multiple Sclerosis: A Case Report Demonstrating Sustained Functional Gains and Cost-Effectiveness.Archives of rehabilitation research and clinical translation · 2025Article
- Article
- Research progress in spasmodic torticollis rehabilitation treatment.World journal of clinical cases · 2024Review
- Health care resource utilization and costs among patients with spasticity or cervical dystonia.Journal of managed care & specialty pharmacy · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSpasticity and cervical dystonia (CD) are movement disorders with considerable direct and indirect healthcare cost implications. Although several studies have discussed their clinical impact, few have calculated the economic burden of these disorders. This study aimed to understand treatment/injection patterns of botulinum toxins type A (BoNT-As) and the characteristics, healthcare resource utilization (HCRU), and costs among patients with spasticity or CD.
methodsRetrospective analyses were conducted using administrative healthcare claims from the IQVIA PharMetrics
resultsOverall, 2452 adults with spasticity, 1364 pediatric patients with spasticity, and 1529 adults with CD were included. Total mean all-cause healthcare costs were US$42,562 (adult spasticity), $54,167 (pediatric spasticity), and $25,318 (CD). Differences were observed in the cost of BoNT-A injection visits between toxins, with abobotulinumtoxinA (aboBoNT-A) having the lowest injection cost across all indications.
conclusionsAboBoNT-A had the lowest injection visit costs across indications. These results are suggestive of real-world resource utilization patterns and costs, and, while helpful in informing insurers' BoNT-A management strategies, further research into cost differences is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.